PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences (OTCBB: DSCI), a manufacturer and marketer of advanced wound care products, today announced it has acquired a global exclusive licensing contract for DSC127, a topical application for the treatment of wounds – such as diabetic ulcers, leg ulcers associated with venous insufficiency, pressure ulcers, and burns – as well as for the reduction of scars resulting from surgical procedures.
